SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides associated with the MeCP2 protein

International Journal of Cancer

Volumn 119, Issue 12, 2006, Pages 2878-2884

  Wang, Zhiqing ^a   Zhang, Jian ^a   Zhang, Yana ^a   Srivenugopal, Kalkunte S ^a   Lim, Seah H ^a,b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Biotherapy and Stem Cell Transplant Program   (United States)

^c TEXAS ONCOLOGY   (United States)

Author keywords

CT antigen; MeCP2 protein; SPAN Xb

Indexed keywords

AZACITIDINE; DINUCLEOTIDE; METHYL CPG BINDING PROTEIN 2; PROTEIN; PROTEIN SPAN XB; TUMOR VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REPORTER GENE; SPAN XB GENE;

BINDING SITES; CELL LINE, TUMOR; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHYL-CPG-BINDING PROTEIN 2; MULTIPLE MYELOMA; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 33751571420     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22259     Document Type: Article

References (17)

1. Westbrook VA, Schoppee PD, Diekman AB, Klotz KL, Allietta M, Hogan KT, Slingluff CL, Patterson JW, Frierson HF, Irvin WP, Jr, Flickinger CJ, Coppola MA, et al. Genomic organization, incidence, and localization of the SPAN-X family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res 2004;10:101-12.
2. Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim SH. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 2003;101:955-60.
3. van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, Andre M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999;94:1156-64.
4. Lim SH, Wang Z, Chiriva-Intemati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001;97:1508-10.
5. Wang Z, Zhang Y, Ramsahoye B, Bowen D, Lim SH. Sp17 expression in myeloma cells is regulated by promoter methylation. Br J Cancer 2004;91:1597-1603.
6. Wang Z, Zhang J, Zhang Y, Lim SH. SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. Int J Cancer 2006;118:1436-44.
7. Rogers SA, Bowen DJ, Ling M, Thomson P, Wang Z, Lim SH. Identification and characterization of a novel gene encoding a SEREX antigen in chronic myeloid leukaemia. Br J Haematol 2002;119:112-14.
8. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-40.
9. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D, Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999;23:58-61.
10. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, Bird A. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992;69:905-14.
11. Wade PA. Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene 2001;20:3166-73.
12. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landberger N, Strouboulis J, Wolfe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91.
13. Ng HH, Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci 2000;25:121-6.
14. Wade PA. Methyl-CpG binding proteins and transcriptional repression. Bioassays 2001;23:1131-7.
15. Lavelle D, Chen YH, Hankewych M, DeSimone J. Histone deacetylase inhibitors increase p21 (WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001;68:170-8.
16. Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004;125:156-61.
17. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-62.